Behind every protocol sits a patient waiting.
Biorce's Aika platform combines advanced AI models with comprehensive clinical trial data to help pharmaceutical and biotech companies design studies faster and more efficiently. The company has raised over €60M in funding from prominent tech investors and expanded internationally with offices in New York, Austin, London, and Lisbon.
- Founded February 2024 by Pedro Coelho, Clara Bernardes, Diogo Pisoeiro, and José Faria
- Aika platform analyzes over 1 million clinical trial records
- €60M+ total funding raised, including €44M Series A in 2026
- Offices in Barcelona, New York, Austin, London, and Lisbon
- Headcount grew from ~60 in 2025 to over 100 by mid-2026
Biorce, a Barcelona-based startup founded in 2024, uses native AI to streamline clinical trials by analyzing over 1 million trial records, reducing design time from months to minutes while improving protocol quality and reducing costs.
Pedro Coelho watched his father fight melanoma. The clinical trial that might save him existed, but finding it, enrolling in it, understanding it—the whole apparatus of modern drug development seemed designed to keep patients at arm's length. When his father died, Coelho carried something with him: the conviction that the system itself was broken, and that artificial intelligence, built with clinical expertise at its core, could fix it.
In February 2024, he and three co-founders—Clara Bernardes, Diogo Pisoeiro, and José Faria—started Biorce in Barcelona. The company's central product is Aika, an AI assistant built specifically for clinical trials. Not a generic tool retrofitted to medicine, but something designed from the ground up to speak the language of regulators, clinicians, and trial designers. Aika does something deceptively simple: it reads. It has ingested more than a million clinical trial records, the accumulated history of regulated human research. When a pharmaceutical company or biotech firm needs to design a new study, Aika can now do in minutes what used to take months—analyzing what has worked before, what pitfalls to avoid, how to structure a protocol that will survive regulatory scrutiny and actually enroll patients.
The technology works by combining advanced AI models with one of the most comprehensive datasets in clinical research. A team of senior clinicians, medical directors, and regulatory specialists can now make informed decisions at speed, rather than disappearing into spreadsheets and precedent for weeks. Aika is designed to augment human judgment, not replace it. It surfaces transparency in processes that are often opaque. It integrates into the heavily regulated workflows that govern drug development—the kind of workflows that do not tolerate surprises.
What distinguishes Biorce from other AI vendors circling healthcare is this: they built for the actual problem, not for the market. The company's internal pilots and customer studies show significant reductions in both time and cost. The current user base skews senior—chief medical officers, heads of regulatory affairs, innovation leaders making strategic decisions about which treatments to pursue and how to test them.
The capital markets noticed. Biorce closed a Series A round of €44 million in 2026, part of a total funding haul exceeding €60 million. The investor roster reads like a who's who of tech founders with conviction: Nik Storonsky from Revolut, Arthur Mensch from Mistral AI, Paulo Rosado from OutSystems, Albert Nieto from Seedtag. These are people who have built at scale and recognize the pattern of a company solving a real bottleneck.
The money has fueled expansion. Biorce now operates from Barcelona, New York, Austin, London, and Lisbon, with North America as the primary market. The headcount has more than doubled in a year—from roughly 60 employees in 2025 to over 100 by mid-2026. The company operates on a subscription model, selling access to pharmaceutical companies, biotech firms, and contract research organizations. The platform analyzes both structured and unstructured data: trial records, scientific literature, regulatory guidance. It automates budget creation for researchers. It accelerates trial timelines. It improves protocol quality.
Biorce has won recognition—Best of Show at SCOPE in both 2025 and 2026, Best Startup at the 4YFN Awards during Mobile World Congress 2026. The company declines to share revenue figures, pointing instead to the funding as evidence of momentum. What they will say is this: growth has been significant since founding.
The guiding principle is simple and patient-centered: one patient at a time. Behind every protocol, every dataset, every trial sits a person waiting. That conviction shapes how Biorce builds and how it works with the biomedical industry. The immediate challenge is scaling without losing the trust and proximity that have made them credible to the sector's leaders. Growth at speed is easy. Growth while staying close to the problem—that is the harder thing.
Citas Notables
Behind each protocol, each dataset and each clinical trial there is a patient waiting— Biorce leadership, describing the company's guiding principle
La Conversación del Hearth Otra perspectiva de la historia
Why does a clinical trial take so long to design in the first place? What's actually happening during those months?
You're designing an experiment on human beings. Every detail matters—who qualifies, what you measure, how you'll know if it worked, what could go wrong. You're also building something that regulators will scrutinize. Most teams are doing this by hand, pulling from memory and past trials, arguing about precedent. It's slow because it's careful. Aika doesn't make it careless. It just makes the careful part faster.
So Coelho's father's experience—that's the origin story. But how does that translate into a business model that actually works?
It translates because the problem is real and universal. Every pharmaceutical company, every biotech firm, every contract research organization faces the same bottleneck. They all need trials designed well and fast. Aika solves that. The subscription model works because the value is immediate and measurable—you save months, you save money, you get to patients sooner.
The investor list is interesting. These are founders, not traditional VCs. What does that tell you?
It tells you they recognize the pattern. Storonsky, Mensch, Rosado—they've all built things that solved real friction in broken systems. They see Biorce doing the same thing in healthcare. That's different from a VC betting on a market thesis. These are people who know what it feels like to build something that actually works.
The company won't share revenue. Does that worry you?
Not particularly. They're pre-profitability, probably. What matters is that they're growing fast enough that serious investors keep writing checks. The €60 million raised is the proof point. If the product wasn't working, if customers weren't seeing value, that money wouldn't have materialized.
What's the real challenge ahead?
Scaling without breaking the thing that made them trustworthy. They've built relationships with leading biomedical organizations because they understand the domain deeply. As they grow to 200, 300, 500 people, that institutional knowledge gets diluted. They have to figure out how to stay close to the problem while moving fast. That's the hard part.